Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85821 trials found · Page 60 of 4292
-
One-Shot cell therapy aims to reset immune system in Tough-to-Treat lupus
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Scientists reprogram Patients' own cells to hunt blood cancer
Disease control Recruiting nowBackground: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often fou…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
One-Shot gene therapy aims to free patients from sickle cell crises
Disease control Recruiting nowThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
Phase: EARLY_PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
New drug trial aims to halt kidney damage in IgA nephropathy
Disease control OngoingThe purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for women with Tough-to-Treat endometrial cancer
Disease control OngoingThe goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC
-
Experimental immune therapy trial offers new hope for Tough-to-Treat muscle disease
Disease control Recruiting nowA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Phase: PHASE2, PHASE3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New pill could offer hope for Tough-to-Treat lung cancer
Disease control Recruiting nowResearchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tiss…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
First patients receive groundbreaking Gene-Targeting drug for inherited ALS
Disease control Recruiting nowThis study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New cell therapy shows promise in battle against returning bone marrow cancer
Disease control Recruiting nowThe goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and…
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC
-
New hope for kids with devastating brain cancer
Disease control Recruiting nowThe goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs targe…
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Major cancer trial tests two promising treatments for tough thyroid tumors
Disease control Recruiting nowThis phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a c…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New hope for AML patients: trial tests promising drug combo against standard care
Disease control Recruiting nowTo compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:19 UTC
-
New treatment strategy aims for Long-Term Cancer-Free status in multiple myeloma patients
Disease control OngoingThe purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negat…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Scientists test antibody cocktail in quest for HIV 'Remission'
Disease control Recruiting nowA5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
New hope for kids with tough cancers: experimental drug trial opens
Disease control Recruiting nowSubstudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lympho…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New hope for breast cancer patients Who've run out of options
Disease control Recruiting nowThe efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have …
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Major global trial aims to protect kidneys and hearts in 11,000 patients
Disease control Recruiting nowThis study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin recepto…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo challenges standard chemo in Tough-to-Treat blood cancer
Disease control OngoingB-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-Ge…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
Major trial aims to outperform standard care for Tough-to-Treat cancer
Disease control Recruiting nowThe purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Scientists test 'Living Drug' to reboot immune system in tough lupus cases
Disease control Recruiting nowThis is a phase l/ll open-label, multicentre, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE systemic lupus erythematosus. In the phase I part, a maximum of n=12 patients will be treated in a maximum of 3 dose levels. In the phase IIa part, a maxi…
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC